BRPI0606170A2 - purificação diastereomérica de rosuvastatina - Google Patents

purificação diastereomérica de rosuvastatina

Info

Publication number
BRPI0606170A2
BRPI0606170A2 BRPI0606170-2A BRPI0606170A BRPI0606170A2 BR PI0606170 A2 BRPI0606170 A2 BR PI0606170A2 BR PI0606170 A BRPI0606170 A BR PI0606170A BR PI0606170 A2 BRPI0606170 A2 BR PI0606170A2
Authority
BR
Brazil
Prior art keywords
rosuvastatin
purification
diastereomeric
diastereomeric purification
diastereomerically pure
Prior art date
Application number
BRPI0606170-2A
Other languages
English (en)
Inventor
Valerie Niddam-Hildesheim
Anna Balanov
Kobi Chen
Natalia Shenkar
Original Assignee
Teva Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma Ltd filed Critical Teva Pharma Ltd
Publication of BRPI0606170A2 publication Critical patent/BRPI0606170A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

PURIFICAçãO DIASTEREOMéRICA DE ROSUVASTATINA. A invenção refere-se a rosuvastatina diastereomericamente pura e processos para preparação de rosuvastatina diastereomericamente pura e seus intermediários. Fórmula (I)
BRPI0606170-2A 2005-10-03 2006-09-12 purificação diastereomérica de rosuvastatina BRPI0606170A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72349105P 2005-10-03 2005-10-03
US73297905P 2005-11-02 2005-11-02
PCT/US2006/035711 WO2007040940A1 (en) 2005-10-03 2006-09-12 Diastereomeric purification of rosuvastatin

Publications (1)

Publication Number Publication Date
BRPI0606170A2 true BRPI0606170A2 (pt) 2009-06-02

Family

ID=37731511

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606170-2A BRPI0606170A2 (pt) 2005-10-03 2006-09-12 purificação diastereomérica de rosuvastatina

Country Status (9)

Country Link
US (2) US20090187026A1 (pt)
EP (1) EP1817293A1 (pt)
JP (1) JP2008526897A (pt)
KR (2) KR20090113920A (pt)
BR (1) BRPI0606170A2 (pt)
CA (1) CA2624801A1 (pt)
IL (1) IL187949A0 (pt)
TW (1) TW200804305A (pt)
WO (1) WO2007040940A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US8318933B2 (en) * 2006-10-31 2012-11-27 Aurobindo Pharma Ltd Process for preparing rosuvastatin calcium
ES2385623T3 (es) * 2007-02-08 2012-07-27 Aurobindo Pharma Limited Un procedimiento mejorado para la preparación de rosuvastatina cálcica
US20090069563A1 (en) 2007-07-12 2009-03-12 Valerie Niddam-Hildesheim Rosuvastatin intermediates and their preparation
EP2022784A1 (en) * 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
WO2009143776A1 (zh) * 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
WO2010035284A2 (en) * 2008-09-26 2010-04-01 Matrix Laboratories Ltd An improved process for the preparation of rosuvastatin calcium
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
EP2467363A1 (en) 2009-08-17 2012-06-27 Aurobindo Pharma Limited Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
ITMI20100753A1 (it) * 2010-04-30 2011-10-31 Dipharma Francis Srl Procedimento per la preparazione di statine
EP2383260A3 (en) * 2010-04-30 2011-12-28 Dipharma Francis S.r.l. Process for the preparation of statins
HU230987B1 (hu) * 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
CN104230817B (zh) * 2013-06-19 2016-09-14 南京欧信医药技术有限公司 3，5-二羟基庚-6-烯酸衍生物的制备方法
CN109580789B (zh) * 2017-09-28 2021-06-22 安徽省庆云医药股份有限公司 一种液相色谱法分离测定瑞舒伐他汀叔丁酯及其光学异构体的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189164A (en) * 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5218138A (en) * 1992-09-02 1993-06-08 Rhone-Poulenc Rorer Pharmaceuticals Inc. Stereoselective reduction of 3-hydroxyket-1-ones to 1,3-syn-dihydroxylated compounds
JPH08301864A (ja) * 1995-05-09 1996-11-19 Toyobo Co Ltd α−オキシ酸の分子間環状ジエステルの精製方法
US5741934A (en) * 1996-04-10 1998-04-21 Sandler; Stanley R. Preparation of primary mercaptans
DE19841342A1 (de) * 1998-09-10 2000-04-20 Merck Patent Gmbh Neue Reaktivsysteme aus polymerisierbaren Monomeren , die Peroxide und stabilisierten Boralkylverbindungen enthalten
JP4565208B2 (ja) * 2000-03-31 2010-10-20 株式会社クレハ グリコリドの精製方法
KR100511533B1 (ko) * 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EP1585736A2 (en) * 2002-05-21 2005-10-19 Ranbaxy Laboratories, Ltd. Process for the preparation of rosuvastatin
JP2004277396A (ja) * 2003-01-23 2004-10-07 Teijin Chem Ltd 芳香族ポリカーボネートから芳香族ジヒドロキシ化合物と炭酸ジアルキルを得る方法
WO2004103977A2 (en) * 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
WO2005023778A2 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
EP1678148A1 (en) * 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
KR20060135712A (ko) * 2003-12-24 2006-12-29 테바 파마슈티컬 인더스트리즈 리미티드 높은 ｓｙｎ형 대 ａｎｔｉ형 비율을 지닌 스타틴의 제조방법
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step

Also Published As

Publication number Publication date
US20090187026A1 (en) 2009-07-23
JP2008526897A (ja) 2008-07-24
KR20070085667A (ko) 2007-08-27
KR20090113920A (ko) 2009-11-02
IL187949A0 (en) 2008-03-20
CA2624801A1 (en) 2007-04-12
US20100197916A1 (en) 2010-08-05
EP1817293A1 (en) 2007-08-15
KR101019450B1 (ko) 2011-03-07
WO2007040940A1 (en) 2007-04-12
TW200804305A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
BRPI0606170A2 (pt) purificação diastereomérica de rosuvastatina
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
NO20080129L (no) Fremgangsmate for fremstilling av dihydrokinazoliner
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX388468B (es) Compuestos multicíclicos y métodos de uso de los mismos.
EA201270149A1 (ru) Ингибиторы bace
EA201000329A1 (ru) Циклические депсипептиды
CR10955A (es) Nuevo procedimiento de sintesis de la agomelatina
MX2012007341A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
ATE517869T1 (de) Herstellung substituierter morphinan-6-one und salzen und zwischenprodukten davon
MX2011012533A (es) Espiro-epoxidos como productos intermedios.
CR10960A (es) Nuevo procedimiento de sintesis de la agomelatina
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
GB0508318D0 (en) Organic compounds
MX2010010597A (es) Procesos para la preparacion de derivados de dioxina benzofusionados.
MX2008001428A (es) Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
ATE517900T1 (de) Heptarylen-und octarylentetracarbonsäurediimide und deren herstellung
CR10934A (es) Nuevo procedimiento de sintesis de la agomelatina
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
MX2009000198A (es) Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo.
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
UA85701C2 (ru) Способ получения ингибиторов триптазы
UA93387C2 (ru) Производные пиримидина и их применение b качестве открывателей калиевых каналов kcnq

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.